Tag:

colon cancer

Latest Headlines

Latest Headlines

Agendia scores $6.8M grant for study of molecular Dx technology in colorectal cancer

Agendia nabbed a $6.8 million grant from the European Commission to use its diagnostic technology to identify certain subtypes of colorectal cancer, a boost for the company as it forges ahead with its products and gains regulatory approval for its tests.

Israeli colon capsule maker reels in $24M in IPO and private placement

Israeli diagnostic outfit Check-Cap raised $24 million in an initial public offering and a simultaneous private placement, giving the company a boost as it looks to develop its disposable imaging capsules for colorectal cancer screening.

Israeli colon capsule maker reels in $24M in IPO and private placement

Israeli diagnostic outfit Check-Cap raised $24 million in an initial public offering and a simultaneous private placement, giving the company a boost as it looks to develop its disposable imaging capsules for colorectal cancer screening.

Exact Sciences wins FDA approval and more for next-gen colon cancer test

Exact Sciences gained FDA premarket approval for its new, cutting-edge colorectal cancer screening test. It is also well ahead in the insurance reimbursement battle.

Exact Sciences wins FDA approval and more for next-gen colon cancer test

Exact Sciences gained FDA premarket approval for its new, cutting-edge colorectal cancer screening test. It is also well ahead in the insurance reimbursement battle.

Exact Sciences raises nearly $120M, focused on a hoped-for 2014 launch of its colon cancer Dx

Exact Sciences President and CEO Kevin Conroy previously promised that 2014 will be all about getting the company's Cologuard colon cancer test to market. Now, the company will be armed with close to $120 million to get the job done.

Exact Sciences raises nearly $120M, focused on a hoped-for 2014 launch of its colon cancer Dx

Exact Sciences President and CEO Kevin Conroy previously promised that 2014 will be all about getting the company's Cologuard colon cancer test to market. Now, the company will be armed with close to $120 million to get the job done.

Exact Sciences' and Epigenomics' colon cancer tests clear FDA panel with mixed results

Two diagnostics companies hoping to improve the rate of early-stage colon cancer detection made it past an FDA panel of experts in late March with mixed results.

Exact Sciences' and Epigenomics' colon cancer tests clear FDA panel with mixed results

Two diagnostics companies hoping to improve the rate of early-stage colon cancer detection made it past an FDA panel of experts in late March with mixed results.

A massive review reaffirms fecal test's place in colon cancer Dx

Scientists continue to push for the development of a more precise, sensitive and cleaner colorectal cancer diagnostic. Now a research team has determined that a simple, at-home test already on the market is highly accurate.
'